Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aadi Bioscience (AADI)
NASDAQ:AADI
Holding AADI?
Track your performance easily
AADI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.21 - $5.70
Previous Close$2.22
Volume196.79K
Average Volume (3M)165.60K
Market Cap
$54.47M
Enterprise Value-$7.20M
Total Cash (Recent Filing)$62.62M
Total Debt (Recent Filing)$946.00K
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Mar 13, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.29
Shares Outstanding24,647,392
10 Day Avg. Volume149,683
30 Day Avg. Volume165,605
Standard Deviation0.21
R-Squared0.03
Alpha-0.00778
Financial Highlights & Ratios
Price to Book (P/B)0.80
Price to Sales (P/S)2.17
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.29
Enterprise Value/Gross Profit-0.33
Enterprise Value/Ebitda0.12
Forecast
1Y Price Target
$1.75Price Target Upside-23.25% Downside
Rating ConsensusHold
Number of Analyst Covering1
Aadi Bioscience News
PremiumCompany Announcements
Aadi Bioscience Reports Q3 2024 Earnings and Growth
PremiumCompany Announcements
Aadi Bioscience Launches Executive Retention Bonus Program
PremiumCompany Announcements
Aadi Bioscience Executives Transition with Continued Roles
Bulls Say, Bears Say
Bulls Say
Financial StabilityCompany will reduce 80% R&D workforce and extend cash runway into at least the second half of 2026.
Product ExclusivityFyarro remains the only preferred treatment for PEComa and continues to see sustained sales with incremental growth expected.
Strategic CollaborationsAadi announced the collaboration with Mirati Therapeutics to study the combination of nab-sirolimus and adagrasib (KRAS inhibitor) in NSCLC and other solid mutations.
Bears Say
Clinical TrialsThe discontinuation of the PRECISION1 study of nab-sirolimus due to low probability of regulatory success highlights significant challenges in achieving approval for this treatment in TSC1/2 solid tumors.
Financial StrategyEnrollment has been paused and workforce reduced significantly as part of cost-saving measures, indicating financial pressure and strategic shifts in resource allocation.
Market PotentialThere is limited growth potential for nab-sirolimus as the existing target market in PEComa may already be saturated, and expansion into other cancer treatments faces hurdles.
---
Ownership Overview
31.22% Insiders
4.07% Mutual Funds
38.66% Other Institutional Investors
22.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AADI FAQ
What was Aadi Bioscience’s price range in the past 12 months?
Aadi Bioscience lowest stock price was $1.21 and its highest was $5.70 in the past 12 months.
What is Aadi Bioscience’s market cap?
Currently, no data Available
When is Aadi Bioscience’s upcoming earnings report date?
Aadi Bioscience’s upcoming earnings report date is Mar 13, 2025 which is in 111 days.
How were Aadi Bioscience’s earnings last quarter?
Aadi Bioscience released its earnings results on Nov 06, 2024. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.458 by -$0.002.
Is Aadi Bioscience overvalued?
According to Wall Street analysts Aadi Bioscience’s price is currently Overvalued.
Does Aadi Bioscience pay dividends?
Aadi Bioscience does not currently pay dividends.
What is Aadi Bioscience’s EPS estimate?
Aadi Bioscience’s EPS estimate is -$0.31.
How many shares outstanding does Aadi Bioscience have?
Aadi Bioscience has 24,647,392 shares outstanding.
What happened to Aadi Bioscience’s price movement after its last earnings report?
Aadi Bioscience reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.458. Following the earnings report the stock price went up 6.533%.
Which hedge fund is a major shareholder of Aadi Bioscience?
Currently, no hedge funds are holding shares in AADI
---
Aadi Bioscience Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.75 (-23.25% Downside)
$1.75 (-23.25% Downside)
Blogger Sentiment
Neutral
AADI Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-51.28%
12-Months-Change
Fundamentals
Return on Equity
-65.95%
Trailing 12-Months
Asset Growth
-38.64%
Trailing 12-Months
Company Description
Aadi Bioscience
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. Its product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 17, 2011 and is headquartered in Cincinnati, OH.
---
AADI Earnings Call
Q2 2024
0:00 / 0:00
---
AADI Stock 12 Month Forecast
Average Price Target
$1.75
▼(-23.25% Downside)
Technical Analysis
---